Abstract 390P
Background
The intensive incidence rate of oropharyngeal cancer in Uzbekistan has increased over the past 7 years from 1.4 to 2.0 per 100,000 population in 2022, and the proportion of active detection has increased from 25.9 to 32.9%.
Methods
A retrospective analysis of the causes and prevalence of oropharyngeal cancer in the Republic of Uzbekistan was performed. The object of the study were 582 patients from database of RSSPMC of Oncology and Radiology of Uzbekistan who were treated for the period 2020-2022. The study of risk factors was carried out according to gradations: smoking, use of a local variety of tobacco - nasvay, alcohol consumption, a history of trauma, a resident of an urban area, working in gas contamination conditions and dustiness. There were 471 men (80.9%), women - 101 (19.1%). The mean age was 47.3±1.5.
Results
A study of geographical indicators demonstrated that the most common oropharyngeal cancer caused by the use of nasvay occurred in patients from the eastern and southern regions of the republic - 327 (56.2%). In these patients, the average duration of tobacco use was more than 7 years. In contrast, poor climatic conditions caused the development of oral cancer in 89 (15.3%) patients from the Aral Sea region (northwest). The remaining 166 (28.5%) patients were in the central regions of Uzbekistan. When studying risk factors, the vast majority of patients (411 (70.6%)) used nasvay as a bad habit. At the same time, 174 (42.3%) of 411 patients also had smoking and alcohol consumption. Despite the impact of the dusty climate in the Aral Sea zone, 81 (91.0%) patients had a history of alcohol consumption, 19 (21.3%) - smoking. 218 (37.5%) urban residents developed oral cancer due to bad habits (smoking - 174, alcohol - 147, nasvay - 53).
Conclusions
Thus, the analysis of the epidemiological aspects of the development of oral cancer in Uzbekistan indicates that this disease is quite widespread and tends to grow. The main factor is bad habits, in particular the widespread use of nasvay. Only, in the urban population, the influence of nasvay on the development of cancer becomes less, but due to the prevalence of smoking and alcohol abuse, it requires further study to identify specific ways to manage oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tashkent medical academy.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract